Patient Disease:
Canine Osteosarcoma
Study Name:
Modulating the Tumor Microenvironment in Osteosarcoma: Adjuvant Immunotherapy Combination with Losartan/Toceranib/Ladarixin
Purpose of the study:
- To investigate the effectiveness of losartan/toceranib/ladarixin in delaying/preventing the development of lung metastasis from osteosarcoma (OS)
Primary Eligibility Criteria:
- Suspected or confirmed diagnosis of osteosarcoma or the limb
- Adequate blood work
- No prior treatment for the primary tumor
- No metastatic disease
- No concurrent immune dysregulation due to an underlying condition or treatment with immune suppressive medications for any condition
- Pets must come to CSU for all visits related to the clinical trial
Study Protocol:
- Dogs will be treated with oral losartan and ladarixin to be given twice daily and oral Palladia given once every other day
- Amputation of the affected limb will be performed 10-14 days after starting treatment
- Recheck two weeks after surgery and then every 4 weeks for exam, blood work, and study blood collection
- Chest x-rays will be rechecked 8 weeks after enrollment, every 4 weeks until week 24, then every 8 weeks
Owner Responsibilities:
- You are responsible for the initial testing to determine study eligibility and any other tests recommended by your pet’s oncologist
- You are expected to make and keep all appointments associated with the study
- You must be comfortable administering oral medications at home
Financial Incentives:
- All costs associated with the trial will be covered up to a total of $5,000
- Toceranib, losartan, and ladarixin will be provided at no cost other than the pharmacy dispensing fee ($8 per prescription)
- Up to $500 is available to treat side effects related to the study drugs
If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.